Posts tagged Matthew Shaw
Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage
Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

ViroCell Biologics confirms a new agreement to address the worldwide viral vector market for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Life Sciences Review, UK CDMO, ViroCell, Great Ormond Street Hospital, John W. Hadden II, Farzin Farzaneh, Matthew Shaw
Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage
Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

Great Ormond Street Hospital (GOSH) has partnered with manufacturer ViroCell Biologics in an effort to address the global viral vector manufacturing bottleneck for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, European Pharmaceutical Manufacturer, UK CDMO, ViroCell, Matthew Shaw, CEO at Great Ormond Street Hospital
ViroCell Biologics announces pivotal partnership with Great Ormond Street
ViroCell Biologics announces pivotal partnership with Great Ormond Street

Innovation-driven viral vector manufacturer, ViroCell Biologics, and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), have announced a new partnership that aims to dislodge the gene and cell therapy bottleneck.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Pharmafile, UK CDMO, Matthew Shaw, CEO at GOSH, Great Ormond Street Hospital
ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”
ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), a world leading children’s hospital, have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Pharmiweb.com, UK CDMO, ViroCell, John W. Hadden II, Farzin Farzaneh, Matthew Shaw, Scientific Advisory Board